What are the indications, dosing guidelines, contraindications, and precautions for fluoxetine?

Fluoxetine: Clinical Overview

FDA-Approved Indications

Fluoxetine is FDA-approved for multiple psychiatric conditions, making it one of the most versatile SSRIs available 1:

• Major depressive disorder (adults and children ≥8 years - the only SSRI approved for pediatric depression)
• Obsessive-compulsive disorder (adults and children)
• Bulimia nervosa
• Panic disorder
• Premenstrual dysphoric disorder
• Bipolar disorder (in combination with olanzapine)

Dosing Guidelines

Major Depressive Disorder

Adults:

• Initial dose: 20 mg once daily in the morning 2
• Maximum dose: 80 mg/day
• Dose increases may be considered after several weeks if insufficient response
• Doses >20 mg/day can be given once daily (morning) or BID (morning and noon)
• Full therapeutic effect may be delayed 4 weeks or longer 2

Pediatric (children and adolescents):

• Start with 10-20 mg/day 2
• For lower weight children: start at 10 mg/day (may remain target dose due to higher plasma levels)
• After 1 week at 10 mg/day, increase to 20 mg/day
• Dose increase to 20 mg/day may be considered after several weeks if insufficient improvement

Weekly dosing option (adults only):

• Prozac Weekly can be initiated 7 days after last daily 20 mg dose
• Used for maintenance after achieving remission with daily dosing 2

Obsessive-Compulsive Disorder

Adults:

• Initial dose: 20 mg/day in the morning 2
• Dose range: 20-60 mg/day (doses up to 80 mg/day have been well tolerated)
• Maximum: 80 mg/day
• Higher doses (60-80 mg) show superior efficacy for OCD 1
• Full therapeutic effect may be delayed until 5 weeks or longer

Pediatric:

• Adolescents and higher weight children: start 10 mg/day, increase to 20 mg/day after 2 weeks
• Dose range: 20-60 mg/day
• Lower weight children: start 10 mg/day
• Dose range: 20-30 mg/day
• Experience with doses >60 mg is minimal

Bulimia Nervosa

• Recommended dose: 60 mg/day administered in the morning 2
• This is the only dose proven statistically superior to placebo
• May titrate up to target dose over several days
• Doses >60 mg/day have not been systematically studied

Special Populations

Hepatic impairment: Use lower or less frequent dosing 2

Renal impairment: Dosage adjustments not routinely necessary 2

Elderly: Consider lower or less frequent dosing 2

Patients on multiple medications or with concurrent disease: Consider lower or less frequent dosing 2

Critical Safety Warnings

Black Box Warning: Suicidality

Fluoxetine carries a black box warning for treatment-emergent suicidality, particularly in adolescents and young adults 1.

• Monitor patients closely beginning 1-2 weeks after initiation 3
• Risk for suicide attempts is greatest during the first 1-2 months of treatment 3
• Monitor for emergence of agitation, irritability, or unusual behavioral changes 3
• Clinically significant suicidal thinking was present in 29% of adolescents at baseline in TADS trial but improved in all treatment groups 4

Pharmacogenetic Considerations

Fluoxetine is metabolized through CYP2D6, which exhibits significant genetic variation 1:

• CYP2D6 poor metabolizers (PMs) have 3.9 to 11.5-fold higher drug exposure and are at higher risk of toxicity 1
• FDA has issued safety labeling changes: use with caution in CYP2D6 PMs and when coadministered with CYP2D6 inhibitors 1
• Use with caution in patients with congenital long QT syndrome, family history of long QT syndrome or sudden cardiac death 1
• Fluoxetine itself acts as a potent CYP2D6 inhibitor, converting approximately 43% of extensive metabolizers to poor metabolizer phenotype with chronic use 1

Contraindications

• Concurrent use with MAOIs or within 14 days of discontinuing an MAOI 2
• Allow at least 5 weeks (perhaps longer) after stopping fluoxetine before starting an MAOI due to long half-life 2

Monitoring and Treatment Modification

Assess patient status, therapeutic response, and adverse effects regularly beginning within 1-2 weeks of initiation 3. This is a strong recommendation based on moderate-quality evidence.

If inadequate response after 6-8 weeks, modify treatment 3:

• Response rate to drug therapy may be as low as 50%
• Consider adding other therapeutic modalities
• Insufficient evidence exists to prefer one agent over another as second-line therapy
• Multiple pharmacologic therapies might be required for nonresponders

Selection Among Antidepressants

When choosing pharmacologic therapy for major depression, select second-generation antidepressants based on adverse effect profiles, cost, and patient preferences 3. This is a strong recommendation from the American College of Physicians.

Key considerations:

• No second-generation antidepressant shows superior efficacy over another 3
• Efficacy does not differ among subgroups based on age, sex, or race/ethnicity 3
• Bupropion is associated with lower rates of sexual adverse events than fluoxetine or sertraline 3
• Paroxetine has higher rates of sexual dysfunction than fluoxetine 3

Common Adverse Effects

Most common side effects (dose-related) 5, 6, 7:

• Nausea
• Nervousness/anxiety
• Insomnia
• Headache
• Anorexia
• Diarrhea

Fluoxetine does not cause anticholinergic effects, orthostatic hypotension, sedation, or significant cardiovascular effects 7. It has a favorable safety profile in overdose compared to tricyclic antidepressants 5, 7.

Drug Interactions

When switching to or from tricyclic antidepressants (TCAs):

• TCA dosage may need reduction
• Monitor plasma TCA concentrations when fluoxetine is coadministered or recently discontinued 2
• Fluoxetine's long half-life (1-3 days for parent compound, 7-15 days for active metabolite norfluoxetine) necessitates prolonged washout periods 5, 6

Important Clinical Pitfalls

1. Delayed onset of action: Full therapeutic effect may take 4-5 weeks or longer; avoid premature dose escalation 2

2. Long half-life implications: The extended half-life protects against withdrawal symptoms but requires longer washout periods when switching medications 5, 6

3. Pediatric depression efficacy concerns: Recent meta-analyses suggest fluoxetine's estimated efficacy in pediatric depression has declined over time into the range of clinical equivalence with placebo when more recent studies are included 8. However, it remains the only FDA-approved SSRI for pediatric depression and showed superior efficacy in the landmark TADS trial 4.

4. Combination therapy for adolescents: Fluoxetine combined with CBT showed the most favorable benefit-risk tradeoff for adolescent depression (71% response rate vs 60.6% for fluoxetine alone, 43.2% for CBT alone, 34.8% for placebo) 4.

5. Weight effects: Fluoxetine significantly reduces body weight, particularly at doses ≥60 mg/day, in short-term interventions (≤12 weeks), and in individuals with obesity 9.